All Studies Meta Analysis Recent:

Influence of a High Vitamin D2 Dose on the Prevention and Improvement of Symptomatic COVID-19 in Health Care Workers: A Multicenter Randomized Clinical Trial

Wang et al., Elsevier BV, doi:10.2139/ssrn.4401710, NCT05673980

Mar 2023

Post
Facebook

Source PDF All Meta

Vitamin D for COVID-19

8th treatment shown to reduce risk in October 2020

^*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.

Lower risk for mortality, ICU admission, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

RCT 214 low risk (no hospitalization) healthcare workers in China, showing no significant differences with vitamin D2 prophylaxis using two bolus treatments.

Patients with higher vitamin D levels (across both groups) were less likely to be infected. The trial only lasted one month. Two thirds of the cases occurred within the first week, when treatment may have minimal impact on vitamin D levels (calcifediol or calcidiol may be more effective due to delays in conversion).

Cases were lower in the intervention group during the last two weeks, after treatment is likely to have increased levels significantly. Regular rather than bolus treatment, longer term treatment, or alternative forms of vitamin D (e.g., calcifediol/calcidiol) may be more effective.

We are not sure of the exact numbers because the supplementary table mentioned is currently unavailable and the numbers in the text are inconsistent. Authors report 50% cases in the vitamin D2 group and 54% control with a total of 104 cases in the ITT analysis, but no counts appear to match these numbers, and details of missing data are not provided.

The study was registered retrospectively. There was no mortality or hospitalization. 200,000 IU vitamin D2 fortnightly.

This is the 27th of 29 COVID-19 RCTs for vitamin D, which collectively show efficacy with p=0.0000024.

This is the 109th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).

Important missing comments or errors? Let us know.

risk of progression, 25.2% lower, RR 0.75, p = 0.15, treatment 99, control 103, combined symptoms.

risk of progression, 4.0% higher, RR 1.04, p = 1.00, treatment 5 of 99 (5.1%), control 5 of 103 (4.9%), risk of severe case, fever.

risk of progression, 7.5% lower, RR 0.92, p = 1.00, treatment 8 of 99 (8.1%), control 9 of 103 (8.7%), NNT 152, risk of severe case, sore throat.

risk of progression, 42.2% lower, RR 0.58, p = 0.41, treatment 5 of 99 (5.1%), control 9 of 103 (8.7%), NNT 27, risk of severe case, rhinorrhea or congestion.

risk of progression, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 99 (0.0%), control 1 of 103 (1.0%), NNT 103, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), risk of severe case, diarrhea.

risk of progression, 13.3% lower, RR 0.87, p = 0.82, treatment 10 of 99 (10.1%), control 12 of 103 (11.7%), NNT 65, risk of severe case, cough.

risk of progression, 48.0% lower, RR 0.52, p = 0.13, treatment 8 of 99 (8.1%), control 16 of 103 (15.5%), NNT 13, risk of severe case, muscle/joint aches.

risk of progression, 56.1% higher, RR 1.56, p = 0.68, treatment 3 of 99 (3.0%), control 2 of 103 (1.9%), risk of severe case, taste/smell.

risk of case, 9.0% lower, RR 0.91, p = 0.57, treatment 49 of 99 (49.5%), control 56 of 103 (54.4%), NNT 21.

risk of case, 12.3% higher, RR 1.12, p = 0.56, treatment 41 of 99 (41.4%), control 38 of 103 (36.9%), first two weeks.

risk of case, 53.8% lower, RR 0.46, p = 0.06, treatment 8 of 99 (8.1%), control 18 of 103 (17.5%), NNT 11, last two weeks.

time to viral-, 10.8% lower, relative time 0.89, treatment 99, control 103.

risk of case, 22.7% lower, RR 0.77, p = 0.19, high D levels (≥30ng/ml) 20 of 44 (45.5%), low D levels (<20ng/ml) 50 of 85 (58.8%), NNT 7.5, outcome based on serum levels.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Wang et al., 29 Mar 2023, Randomized Controlled Trial, China, preprint, median age 36.5, 23 authors, study period 18 December, 2022 - 20 February, 2023, dosage 200,000IU days 1, 14, trial NCT05673980 (history). Contact: schl@bjmu.edu.cn, lianglbh@126.com, haiyanli1027@hotmail.com.

This Paper Vitamin D All

Influence of a High Vitamin D2 Dose on the Prevention and Improvement of Symptomatic COVID-19 in Health Care Workers: A Multicenter Randomized Clinical Trial

Huan Wang, PhD Liyuan Tao, Liyan Cui, Yahong Chen, Dongyang Liu, Lixiang Xue, Yuping Yang, Yang Lv, Fuchun Zhang, Tiancheng Wang, Xiaoxiao Wang, Wanqiong Yuan, Hao Liu, Jie Huang, Yanfang Jiang, Na Liu, Lijuan Yang, Yunjing Hu, Yanfang Li, Yuling Gao, Dr Haiyan Li, Baohua Li, PhD Chun-Li Song

Background COVID-19 pandemic exacerbates infections among health care workers, highlighting importance of prevention for these high-risk people. Vitamin D, as an immunomodulator, is thought likely to be to correlate with the inflammatory reaction. Methods This was a multicenter, open-label, randomized controlled trial. The study recruited 228 health care workers who tested negative PCR or antigen for COVID-19. Subjects were randomly allocated to 200, 000 IU vitamin D2 fortnightly or non-intervention at a ratio 1:1. PCR or antigen tests were taken at baseline and twice a week during the follow-up visit. The concentration of serum 25-hydroxyvitamin D (25(OH)D), C-reaction protein (CRP), complement component C1q and inflammatory cytokines (IL-1β, IFN-α, IFN-

Article Information Corresponding Author: Chunli Song, Baohua Li, Haiyan Li This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4401710 P r e p r i n t n o t p e e r r e v i e w e d Conflict of Interest Disclosures: The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Ardebili, Naserbakht, Bernstein, Alazmani-Noodeh, Hakimi et al., Healthcare providers experience of working during the COVID-19 pandemic: A qualitative study, Am J Infect Control

Baeke, Takiishi, Korf, Gysemans, Mathieu, Vitamin D: modulator of the immune system, Curr Opin Pharmacol

Bassatne, Chakhtoura, Saad, Fuleihan, Vitamin D supplementation in obesity and during weight loss: A review of randomized controlled trials, Metabolism

Bishop, Ismailova, Dimeloe, Hewison, White, Vitamin D and Immune Regulation: Antibacterial, Antiviral, Anti-Inflammatory, JBMR Plus

Brunner, Wactawski-Wende, Caan, The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial, Nutr Cancer

Campbell, Spector, Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1, Autophagy

Castillo, Costa, Barrios, Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study, J Steroid Biochem Mol Biol

Cegolon, Ronchese, Ricci, Negro, Larese-Filon, SARS-CoV-2 Infection in Health Care Workers of Trieste (North-Eastern Italy), 1, Viruses

Chambers, Hawrylowicz, The impact of vitamin D on regulatory T cells, Curr Allergy Asthma Rep

De La Guía-Galipienso, Martínez-Ferran, Vallecillo, Lavie, Sanchis-Gomar et al., Vitamin D and cardiovascular health, Clin Nutr

Dhama, Nainu, Frediansyah, Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies, J Infect Public Health

Feikin, Higdon, Abu-Raddad, Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression, Lancet

Goltzman, Functions of vitamin D in bone, Histochem Cell Biol

Holick, Binkley, Bischoff-Ferrari, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab

Ismailova, White, Vitamin D, infections and immunity, Rev Endocr Metab Disord

Jean, Souberbielle, Chazot, Vitamin D in Chronic Kidney Disease and Dialysis Patients, Nutrients

Khazai, Judd, Tangpricha, Calcium and vitamin D: skeletal and extraskeletal health, Curr Rheumatol Rep

Klug-Micu, Stenger, Sommer, CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes, Immunology

Lips, De Jongh, Van Schoor, Trends in Vitamin D Status Around the World, JBMR Plus

Lips, Van Schoor, The effect of vitamin D on bone and osteoporosis, Best Pract Res Clin Endocrinol This

Malihi, Lawes, Wu, Monthly high-dose vitamin D supplementation does not increase kidney stone risk or serum calcium: results from a randomized controlled trial, Am J Clin Nutr

Mohan, Cherian, Sharma, Exploring links between vitamin D deficiency and COVID-19, PLoS Pathog

Mozaffari-Khosravi, Hosseinzadeh-Shamsi-Anar, Salami, Hadinedoushan, Mozayan, Effects of a single post-partum injection of a high dose of vitamin D on glucose tolerance and insulin resistance in mothers with first-time gestational diabetes mellitus, Diabet Med

Murai, Fernandes, Sales, Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial, JAMA

Seal, Bertenthal, Carey, Grunfeld, Bikle et al., Association of Vitamin D Status and COVID-19-Related Hospitalization and Mortality, J Gen Intern Med

Wong, Chan, Yuen, Infection of healthcare workers despite a high vaccination rate during the fifth wave of COVID-19 due to Omicron variant in Hong Kong, Infect Prev Pract

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0